SPRB — Spruce Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $89.27m
- $79.14m
- $4.91m
Annual cashflow statement for Spruce Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -29.5 | -42.3 | -46.2 | -47.9 | -53 |
| Depreciation | |||||
| Non-Cash Items | 0.821 | 4.39 | 3.29 | 4.22 | 5.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.16 | 1.96 | 1.13 | 10.4 | -8.57 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -27.5 | -35.9 | -41.7 | -33.3 | -56 |
| Capital Expenditures | -0.074 | -0.093 | -0.008 | -0.007 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -79.1 | 23.7 | 55.8 | 0 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.074 | -79.2 | 23.7 | 55.8 | 0 |
| Financing Cash Flow Items | -2.9 | -0.039 | -0.319 | -3.03 | -0.246 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 181 | 0.643 | -0.241 | 49.1 | -1.62 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 153 | -114 | -18.2 | 71.6 | -57.6 |